Results 51 to 60 of about 1,440 (183)

A Rare Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Occurred in Postchemotherapy of Breast Cancer

Case Reports in Hematology, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy that arises from plasmacytoid dendritic cells.
Jiankun Tong, Sergei Aksenov, Beth M. Siegel, Lihong Wei, William H. Rodgers   +4 more
doaj   +1 more source

A case report on BPDCN: Blastic Plasmacytoid Dendritic Cell Neoplasm

World Journal of Advanced Research and Reviews, 2023
Dendritic cells are present in both lymphoid and non-lymphoid organs, which are heterogenous group of nonphagocytic and nonlymphoid immune accessory cells. Plasmacytoid dendritic cell (which has an eccentric nuclei) are subset of dendritic cells aid in secreting high levels of type 1 interferons by activation and gaining dendritic cell like morphology,
Mercy Paul M, Sukumar Naidu KD
openaire   +2 more sources

Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report

eJHaem, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123‐directed cytotoxin, Tagraxofusp, is a targeted therapy for BPDCN. Here, we
Jad Sibai, RuiQi Chen, Ibrahim Al Nabhani, Maria Agustina Perusini, Hassan Sibai   +4 more
doaj   +1 more source

Targeted diphtheria toxin to treat BPDCN

Blood, 2014
In this issue of Blood, Frankel et al describe a novel treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) using an engineered version of diphtheria toxin that is targeted to malignant cells via a fusion with interleukin (IL)3 (see panel A).
openaire   +3 more sources

Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel

HemaSphere, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a hematological malignancy characterized by recurrent skin nodules, an aggressive clinical course with rapid involvement of hematological organs, and a poor prognosis with overall survival.
Livio Pagano, Pier Luigi Zinzani, Stefano Pileri, Pietro Quaglino, Branko Cuglievan, Emilio Berti, Naveen Pemmaraju, Francesco Onida, Rein Willemze, Alberto Orfao, Giovanni Barosi   +10 more
doaj   +1 more source

Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting [PDF]

Journal of Immunotherapy and Precision Oncology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic malignancy with limited treatment options.
Prajwal Dhakal, Mario Sy, Grerk Sutamtewagul, Eric Mou, Nanmeng Yu, Naveen Pemmaraju   +5 more
doaj   +1 more source

Unusual presentation of blastic plasmacytoid dendritic cell neoplasm: Pitfalls in other hematolymphoid neoplasms

Human Pathology: Case Reports, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+/CD56+ hematological malignancy with aggressive clinical course and poor prognosis.
Alexis Trecourt, Brigitte Balme, Marie-Hélène Lorton, Juliette Fontaine, Pauline Desormeaux, Cédric Rossi, Jean-Noël Bastie, Ingrid Lafon, Géraldine Jeudy, Sophie Dalac, Sarah Huet, Pierre Sujobert, Claire Mauduit, Alexandra Traverse-Glehen   +13 more
doaj   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for BPDCN

Biology of Blood and Marrow Transplantation, 2020
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy arising from plasmacytoid dendritic cells. It commonly presents as skin lesions with or without bone marrow, lymph node or systemic involvement. Limited retrospective data have shown durable remissions after allogeneic (allo) hematopoietic cell
Muzaffar H. Qazilbash, Jeremy Ramdial, Qaiser Bashir, Denai R Milton, Romil D. Patel, Uday R. Popat, Chitra M. Hosing, Partow Kebriaei, Amin M. Alousi, Stefan O. Ciurea, Marina Konopleva, Richard E. Champlin, Naveen Pemmaraju   +12 more
openaire   +1 more source

How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network

Blood, 2015
Abstract Blastic plasmacytoid dendritic cell neoplasm is a rare and aggressive neoplasm for which there is still no current consensus on the best therapeutic approach. Most patients respond to intensive chemotherapy, but relapses are almost inevitable with median overall survival (OS) in the largest patient series ranging from 8 to 12 ...
Eve Poret, Chrystelle Vidal, Yohan Desbrosses, Fanny Angelot Delettre, Maider Pagadoy, Aurore Pugin, Louis Benazet, Franck Leroux, Elise Robert, Delphine Binda, Sabeha Biichle, Anne Roggy, Laure Philippe, Berengere Gruson, Anne-Claire Gac, Michel Maigre, Denis Caillot, Remy Gressin, Pascal Turlure, Anne-Sophie Michallet, Lila Gilis, Veronique Dorvaux, Yazid Arkam, Caroline Bonmati, Pierre Péterlin, Pierre-Simon Rohrlich, Thorsten Braun, jean-Valere Malfuson, Didier Bouscary, Eric Pujade-Lauraine, Felipe Suarez, Carole Soussain, Etienne Lengliné, Mathieu Puyade, Tony Marchand, Denis Guyotat, Bruno Lioure, Christian Recher, Damien Roos-Weil, Fabrice Jardin, Jean-Pierre Marolleau, Bernard Drenou, Bernard Bonnotte, Sophie Dalac, Philippe Saas, Francine Garnache Ottou, Eric Deconinck   +46 more
openaire   +1 more source